> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novo Nordisk Announces Favorable CV Data on Victoza
- URL: https://www.fdaweb.com/novo-nordisk-announces-favorable-cv-data-on-victoza/
- Published: 2016-06-14T12:00:00.000Z
- Updated: 2026-09-14T21:09:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135935

Novo Nordisk says its diabetes drug Victoza (liraglutide) injection 1.2 mg or 1.8 mg reduced the risk of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo in a recent trial involving 9,340 adults. “Victoza is the only approved GLP-1 receptor agonist to demonstrate a superior reduction of major CV events vs placebo, both on top of standard of care, in a cardiovascular outcomes trial,” the [company says](http://press.novonordisk-us.com/News-Releases?item=122866&ref=fdaweb.com). “The expanded CV endpoint was significantly reduced by 12% with Victoza compared to placebo (95% CI: 0.81; 0.96, p=0.005). The expanded CV endpoint included the three components of the primary endpoint in addition to unstable angina leading to hospitalization, coronary revascularization and hospitalization for heart failure.

The company’s stock was down 5% in mid-day trading due to analysts’ concerns the results were lower than expected. The trial results were apparently not as favorable as recent results from Boehringer Ingelheim and Eli Lilly on Jardiance (empagliflozin). In its trial, Jardiance was shown to significantly reduce the risk of CV death, non-fatal heart attack or non-fatal stroke by 14% versus placebo, the companies say. “Risk of CV death was reduced by 38%, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke,” they say. “Treatment with Jardiance also resulted in a 32% reduction in all-cause mortality and a 35% reduction in hospitalization for heart failure. The companies have already submitted a supplemental NDA ([see story](http://www.fdaweb.com/login.php?sa=v&aid=D5134555&searchWords=jardiance&cate=S&stid=%241%24ck5.%2Fp1.%24ZCTrNr0MR1Sv%2FB%2FKwXG4n0)) to revise product labeling and an advisory committee will review the submission later this month.